Skip to main content

Is Adcetris a chemotherapy drug?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on Feb 22, 2025.

Official Answer by Drugs.com

Adcetris is a targeted drug used to treat cancer but is not a traditional chemotherapy. Adcetris is made up of 3 parts:

Adcetris combines the antibody and cancer drug, allowing the antibody to direct the drug to a target on lymphoma cancer cells known as CD30. The cancer drug is monomethyl auristatin E (MMAE), which inhibits microtubule polymerization and leads to cell death.

What type of drug is Adcetris?

Adcetris is known as a CD30-directed Antibody Drug conjugate (ADC). It belongs to a group of targeted drug therapies called monoclonal antibodies.

What does Adcetris treat?

Adcetris (brentuximab vedotin) is a prescription drug used in adults and children to treat different types of blood cancers (lymphomas). Adcetris is used to treat certain forms of classical Hodgkin lymphoma (cHL) and T-cell lymphomas (a form of non-Hodgkin lymphoma).

It is given as an intravenous (IV) infusion into your vein. Specifically Adcetris treats:

Classical Hodgkin Lymphoma:

Certain types of B-cell lymphoma in adults:

Certain types of T-cell lymphoma in adults:

This is not all the information you need to know about Adcetris (brentuximab vedotin) for safe and effective use and does not take the place of your doctor’s directions. Review the full prouct information and discuss this information and any questions you have with your doctor or other health care provider.

Related questions

References
  • Adcetris (brentuximab vedotin) prescribing information. Revised 2/2025. Accessed Feb 22, 2025 at https://labeling.pfizer.com/ShowLabeling.aspx?id=20629
  • Bradley AM, Devine M, DeRemer D. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate. Am J Health Syst Pharm. 2013 Apr 1;70(7):589-97. doi: 10.2146/ajhp110608. PMID: 23515511.

Read next

What are CHOP and R-CHOP chemotherapy regimens?

CHOP and R-CHOP are two chemotherapy regimens. CHOP contains cyclophosphamide, doxorubicin, vincristine, and prednisone, while R-CHOP adds rituximab. R-CHOP is the standard treatment for most patients with B-cell non-Hodgkin lymphomas, especially DLBCL, due to its superior efficacy.

Continue reading

What is the difference between Truxima and Rituxan?

Truxima (rituximab-abbs) is a biosimilar to Rituxan (rituximab). While both drugs are CD20-directed cytolytic antibodies used to treat non-Hodgkin’s lymphoma (NHL), Rituxan has additional FDA-approved indications beyond NHL. Continue reading

What is the success rate of Rituxan (rituximab) in patients with blood cancers?

In patients with hematological or blood cancers, including non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), Rituxan’s success is measured in a number of ways. It is measured by looking at how long patients responded to treatment (median duration of response), how long they live without their disease progressing (progression-free survival) and how many patients respond to treatment (response rate).

Rituxan treatment improves outcomes in certain patients with NHL. Adding Rituxan alongside standard therapies enhances the response patients have to treatment and improves overall outcomes, including increasing the time patients live for without experiencing a progression of their disease.

Rituxan helps to improve overall survival in certain patients with CLL and also helps to increase the time patients live for without experiencing disease progression. Adding Rituxan alongside standard therapy enhances the response patients have to therapy. Continue reading

See also:

Related medical questions

Drug information

Related support groups